Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ThromboGenics, a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, has announced that Patrik De Haes, currently COO, has been appointed to succeed Desire Collen as the company's new CEO on September 1, 2008.
Subscribe to our email newsletter
Dr Collen will remain chairman of ThromboGenics’s board of directors. This new structure is said to ensure the continuity of ThromboGenics’s senior management.
Prior to joining ThromboGenics, Dr De Haes was head of the global insulin infusion business at Roche Diagnostics in Bern, Switzerland.
Dr Collen said: “I am glad that Patrik has agreed to become ThromboGenics’s new CEO. His significant international management experience and his contribution to the company’s success over the last 18 months gives me great confidence that ThromboGenics will continue to prosper under his leadership.”